%0 Journal Article
%T Cytoreductive nephrectomy following treatment with anti-vascular endothelial growth factor-targeted agents: is it surgically safe?
%A Hideaki Miyake
%J SCIE-indexed Journal
%D 2019
%R 10.21037/atm.2019.09.106
%X In the era of cytokine therapy, 2 prospective randomized clinical trials (RCTs) demonstrated significantly more superior overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients receiving cytoreductive nephrectomy followed by interferon-¦Á (IFN-¦Á) than of those treated with IFN-¦Á alone (1,2); therefore, it has been recognized as a standard therapeutic approach for mRCC patients to perform cytoreductive nephrectomy prior to the introduction of systemic therapy
%U http://atm.amegroups.com/article/view/29775/html